Table III.

Univariate and multivariate Cox proportional-hazard regression analysis of recurrence free survival in patients with hepatocellular carcinoma.

	Univariate analysis			Multivariate analysis
Characteristic	HR	95% CI	P-value	HR	95% CI	P-value
Age, ≥65 vs. <65 years	1.01	0.71–1.43	0.98
Sex, male vs. female	1.27	0.77–2.10	0.35
Virus infection, HCV vs. others	1.28	0.88–1.85	0.19
Albumin, <3.5 vs. ≥3.5 g/dl	1.74	1.13–2.68	0.01	1.17	0.59–2.35	0.65
PT, <70 vs. ≥70%	1.12	0.67–1.84	0.67
ICG-R15, ≥15 vs. <15%	2.06	1.31–3.26	0.002	1.17	0.60–2.29	0.64
Liver cirrhosis, (+) vs. (−)	1.31	0.91–1.88	0.14
Child-Pugh classification, B vs. A	1.24	0.60–2.53	0.56
Liver damage, B or C vs. A	1.97	1.26–3.08	0.003	1.91	0.88–4.14	0.10
Tumour number, multiple vs. solitary	1.61	1.07–2.42	0.02	1.44	0.66–3.17	0.35
Tumour size, ≥2 vs. <2 cm	1.73	0.97–3.09	0.06
AFP, ≥20 vs. <20 ng/ml	1.46	1.02–2.08	0.04	1.43	0.88–2.34	0.15
Differentiation, poor vs. good/moderate	1.58	0.85–2.94	0.15
Growth form, infiltrative vs. expansive	1.49	0.92–2.42	0.10
Formation of capsule, (−) vs. (+)	1.27	0.84–1.91	0.25
Infiltration to capsule, (+) vs. (−)	1.06	0.74–1.51	0.77
Septal formation, (−) vs. (+)	1.00	0.68–1.47	0.99
Serosal invasion, (+) vs. (−)	2.00	1.33–3.02	0.0009	2.39	1.30–4.42	0.005
Portal vein or hepatic vein invasion, (+) vs. (−)	2.36	1.57–3.54	<.0001	2.82	1.26–6.28	0.01
Surgical margin, (+) vs. (−)	1.32	0.81–2.13	0.26
Stage, III/IV vs. I/II	1.46	1.01–2.10	0.04	0.65	0.28–1.51	0.32
YTHDF1 expression, high vs. low	1.60	1.11–2.31	0.01	1.37	0.83–2.27	0.21
YTHDF2 expression, high vs. low	1.82	1.20–2.76	0.004	1.85	1.09–3.15	0.02

PT, prothrombin time; ICG-R15, indocyanine green 15-min clearance rate; AFP, α-fetoprotein; HCV, hepatitis C virus; YTHDF1/2, YT521-B homology domain family 1/2; HR, hazard ratio.